Fiera Capital (Canada)
BBIO icon

Fiera Capital (Canada)’s BridgeBio Pharma BBIO Stock Holding History

Fiera Capital (Canada)’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.5M Sell
316,101
-6,589
-2% -$462K 0.09% 161
2026
Q1 		$24M Buy
+322,690
New +$23.4M 0.08% 177

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Fiera Capital (Canada)'s BBIO Position: Q2 2026 in Review

Fiera Capital (Canada) reduced its BridgeBio Pharma (BBIO) stake by 2% in Q2 2026, selling an estimated $462K and leaving 316,101 shares worth $23.5M. The position accounts for 0.09% of the portfolio, ranked #161.

Fiera Capital (Canada) first reported a position in BBIO in Q1 2026 and has held it in 2 quarters since. The position peaked at $24M in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Fiera Capital (Canada) held 316,101 shares of BridgeBio Pharma worth $23.5M as of Q2 2026.
  • Fiera Capital (Canada) sold 6,589 BridgeBio Pharma shares in Q2 2026, an estimated $462K.
  • BridgeBio Pharma made up 0.09% of Fiera Capital (Canada)'s portfolio in Q2 2026, its #161 holding.
  • Fiera Capital (Canada) first reported a position in BridgeBio Pharma in Q1 2026 and has held it in 2 quarters since.
  • Fiera Capital (Canada)'s BridgeBio Pharma position peaked at $24M in Q1 2026.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Fiera Capital (Canada)'s 13F filing for Q2 2026, filed 7 Aug 2026.